IN

Incanthera plc

Develops targeted dermatology & oncology therapies using unique formulation & delivery technologies.

INC | Aquis Stock Exchange

Overview

Corporate Details

ISIN(s):
GB00BGL7YW15 (+1 more)
LEI:
2138002HEV4UFBOEXQ97
Country:
United Kingdom
Address:
C/O GATELEY LEGAL, M2 4WU MANCHESTER
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Incanthera plc is a therapeutics company specializing in the fields of dermatology and oncology. The company focuses on discovering and developing targeted solutions and transformative treatment technologies to address unmet medical needs. It leverages unique formulation and delivery technologies for its product pipeline. Incanthera's current commercial focus is its proprietary skincare brand, SKIN + CELL, which offers dermatological applications developed from its core technologies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-10 12:15
Post-Annual General Meeting Information
AGM 2025 Presentation Materials
English 17.0 KB
2025-11-07 15:40
Post-Annual General Meeting Information
Result of AGM
English 32.4 KB
2025-11-06 08:30
Pre-Annual General Meeting Information
AGM 2025 Update
English 16.0 KB
2025-10-16 11:15
Investor Presentation
Proactive Investor Forum Presentation
English 18.0 KB
2025-10-14 08:00
Pre-Annual General Meeting Information
Notice of AGM
English 20.7 KB
2025-08-11 08:00
Earnings Release
SKIN + CELL COMMERCIAL WEBSITE NOW OPEN FOR SALES
English 21.4 KB
2025-08-06 08:00
Regulatory News Service
SKIN + CELL TO LAUNCH
English 24.3 KB
2025-07-09 08:00
Major Shareholding Notification
Holding(s) in Company
English 52.6 KB
2025-06-30 08:00
Share Issue/Capital Change
Subscription, Directors' Dealing and RPT
English 51.7 KB
2025-06-18 08:00
Environmental & Social Information
New Findings on Protective Effects of Skin + CELL
English 21.1 KB
2025-03-28 08:00
Regulatory News Service
Commercial Update
English 19.0 KB
2025-03-25 16:08
Legal Proceedings Report
Resolution of Allegations of Patent Infringement
English 19.3 KB

Automate Your Workflow. Get a real-time feed of all Incanthera plc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Incanthera plc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Incanthera plc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Oruka Therapeutics, Inc. Logo
Develops long-acting antibody therapies for chronic inflammatory and skin diseases.
United States of America
ORKA
Orum Therapeutics, Inc. Logo
Developing degrader-antibody conjugates for cell-selective protein degradation to treat cancer.
South Korea
475830
OSR Holdings, Inc. Logo
Acquires biopharma R&D platforms to build a diverse portfolio of healthcare therapies.
United States of America
OSRH
OS Therapies Inc Logo
Developing a cancer vaccine to treat HER2-expressing tumors, primarily Osteosarcoma.
United States of America
OSTX
Otsuka Holdings Co., Ltd. Logo
Global healthcare group creating pharmaceuticals and nutraceuticals for worldwide well-being.
Japan
4578
Outlook Therapeutics, Inc. Logo
Developing an ophthalmic bevacizumab to treat retinal diseases like wet AMD.
United States of America
OTLK
Ovid Therapeutics Inc. Logo
Developing targeted small molecule therapies for rare neurological diseases and epilepsies.
United States of America
OVID
Ovoca Bio Plc Logo
Biopharma developing a novel therapy for premenopausal women with low sexual desire (HSDD).
Ireland
OVXA
Oxford Biomedica PLC Logo
A CDMO for cell & gene therapy, providing end-to-end viral vector development & manufacturing.
United Kingdom
OXB
OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC Logo
A former biopharma firm that developed non-addictive, cannabinoid-based pain therapies.
United Kingdom
OCTHF

Talk to a Data Expert

Have a question? We'll get back to you promptly.